CA2479638C - Hfa-suspension formulations of crystalline tiotropium bromide anhydrate - Google Patents
Hfa-suspension formulations of crystalline tiotropium bromide anhydrate Download PDFInfo
- Publication number
- CA2479638C CA2479638C CA2479638A CA2479638A CA2479638C CA 2479638 C CA2479638 C CA 2479638C CA 2479638 A CA2479638 A CA 2479638A CA 2479638 A CA2479638 A CA 2479638A CA 2479638 C CA2479638 C CA 2479638C
- Authority
- CA
- Canada
- Prior art keywords
- hfa
- acid
- contain
- suspensions
- tiotropium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Abstract
The invention relates to propellant formulations containing suspensions of a crystalline anhydrate of (1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane bromide.
Description
' CA 02479638 2004-09-16 80282pct.210 HFA suspension formulations of an anhydrite The invention relates to propellant gas preparations for metered-dose aerosols with suspension formulations of the crystalline anhydrite of (1a,2a,4[i,5a,7[i)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02'4]nonane-bromide.
Background to the invention o The compound (1a,2[i,4[i,5a,7[3)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02'4]nonane-bromide, is known from European Patent Application EP 418 716 A1 and has the following chemical structure:
+ Me Me~N, O _ ~H Br O
S ~--0 //~OH
~5 The compound has valuable pharmacological properties and is known by the name tiotropium bromide (BA679). Tiotropium bromide is a highly effective anticholinergic and can therefore provide therapeutic benefit in the treatment of asthma or COPD
(chronic obstructive pulmonary disease).
2o Tiotropium bromide is preferably administered by inhalation.
The aim of the present invention is to prepare HFA-metered-dose aerosols containing tiotropium bromide as the sole active ingredient in suspended form.
25 Detailed descJation of the invention It has been found that, depending on the choice of conditions which can be used when purifying the crude product obtained after industrial manufacture, tiotropium bromide occurs in various crystalline modifications.
3o It has been found that these different modifications can be deliberately produced by selecting the solvents used for the crystallisation as well as by a suitable choice of the process conditions used in the crystallisation process. One of these crystalline modifications is the crystalline monohydrate of tiotropium bromide.
It has now surprisingly been found that starting from this crystalline monohydrate of tiotropium bromide which is not yet known in the art it is possible to obtain an anhydrous crystal modification of tiotropium bromide (tiotropium anhydrate) which is exceptionally suitable for the preparation of suspensions in the propellant gases HFA
227 and/or HFA 134a for administration by inhalation.
to Accordingly, the present invention relates to suspensions of this crystalline tiotropium bromide anhydrate in the propellant gases HFA 227 and/or HFA 134a, optionally in adm fixture with one or more other propellant gases, preferably selected from the group consisting of propane, butane, pentane, dimethylether, CHCIF2, CHZF2, CF3CH3, isobutane, isopentane and neopentane.
Where reference is made within the scope of the present invention to crystalline tiotropium bromide anhydrate this should be taken as a reference to the anhydrous crystalline modification of tiotropium bromide which can be obtained by drying the crystalline tiotropium bromide monohydrate. This crystal modification is also optionally known within the scope of the present invention as crystalline tiotropium bromide in anhydrous form.
Preferred suspensions according to the invention are those which contain as propellant gas HFA 227 on its own, a mixture of HFA 227 and HFA 134a or HFA
134a on its own.
If a mixture of propellant gases HFA 227 and HFA 134a is used in the suspension formulations according to the invention, the weight ratios in which these two propellant gas components are used may be freely selected.
If in the suspension formulations according to the invention one or more other 3o propellant gases are used in addition to the propellant gases HFA 227 and/or HFA
134a , selected from the group consisting of propane, butane, pentane, dimethylether, CHCIF2, CHZF2, CF3CH3, isobutane, isopentane and neopentane, the proportion of this other propellant gas component is preferably less than 50 %, preferably less than 40%, more preferably less than 30%.
The suspensions according to the invention preferably contain between 0.001 and 0.8% tiotropium. Suspensions which contain 0.08 to 0.5%, more preferably 0.2 to 0.4% tiotropium are preferred according to the invention.
Background to the invention o The compound (1a,2[i,4[i,5a,7[3)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02'4]nonane-bromide, is known from European Patent Application EP 418 716 A1 and has the following chemical structure:
+ Me Me~N, O _ ~H Br O
S ~--0 //~OH
~5 The compound has valuable pharmacological properties and is known by the name tiotropium bromide (BA679). Tiotropium bromide is a highly effective anticholinergic and can therefore provide therapeutic benefit in the treatment of asthma or COPD
(chronic obstructive pulmonary disease).
2o Tiotropium bromide is preferably administered by inhalation.
The aim of the present invention is to prepare HFA-metered-dose aerosols containing tiotropium bromide as the sole active ingredient in suspended form.
25 Detailed descJation of the invention It has been found that, depending on the choice of conditions which can be used when purifying the crude product obtained after industrial manufacture, tiotropium bromide occurs in various crystalline modifications.
3o It has been found that these different modifications can be deliberately produced by selecting the solvents used for the crystallisation as well as by a suitable choice of the process conditions used in the crystallisation process. One of these crystalline modifications is the crystalline monohydrate of tiotropium bromide.
It has now surprisingly been found that starting from this crystalline monohydrate of tiotropium bromide which is not yet known in the art it is possible to obtain an anhydrous crystal modification of tiotropium bromide (tiotropium anhydrate) which is exceptionally suitable for the preparation of suspensions in the propellant gases HFA
227 and/or HFA 134a for administration by inhalation.
to Accordingly, the present invention relates to suspensions of this crystalline tiotropium bromide anhydrate in the propellant gases HFA 227 and/or HFA 134a, optionally in adm fixture with one or more other propellant gases, preferably selected from the group consisting of propane, butane, pentane, dimethylether, CHCIF2, CHZF2, CF3CH3, isobutane, isopentane and neopentane.
Where reference is made within the scope of the present invention to crystalline tiotropium bromide anhydrate this should be taken as a reference to the anhydrous crystalline modification of tiotropium bromide which can be obtained by drying the crystalline tiotropium bromide monohydrate. This crystal modification is also optionally known within the scope of the present invention as crystalline tiotropium bromide in anhydrous form.
Preferred suspensions according to the invention are those which contain as propellant gas HFA 227 on its own, a mixture of HFA 227 and HFA 134a or HFA
134a on its own.
If a mixture of propellant gases HFA 227 and HFA 134a is used in the suspension formulations according to the invention, the weight ratios in which these two propellant gas components are used may be freely selected.
If in the suspension formulations according to the invention one or more other 3o propellant gases are used in addition to the propellant gases HFA 227 and/or HFA
134a , selected from the group consisting of propane, butane, pentane, dimethylether, CHCIF2, CHZF2, CF3CH3, isobutane, isopentane and neopentane, the proportion of this other propellant gas component is preferably less than 50 %, preferably less than 40%, more preferably less than 30%.
The suspensions according to the invention preferably contain between 0.001 and 0.8% tiotropium. Suspensions which contain 0.08 to 0.5%, more preferably 0.2 to 0.4% tiotropium are preferred according to the invention.
By tiotropium is meant the free ammonium cation. The propellant gas suspensions according to the invention are characterised in that they contain tiotropium in the form of the crystalline tiotropium bromide anhydrate which is exceptionally suitable for this application. Accordingly, the present invention preferably relates to suspensions which contain between 0.0012 and 96% crystalline tiotropium bromide anhydrate. Of particular interest according to the invention are suspensions which contain 0.096 to 0.6%, more preferably 0.24 to 0.48% crystalline tiotropium bromide anhydrate.
o The percentages specified within the scope of the present invention are always percent by mass. If parts by mass of tiotropium are given in percent by mass, the corresponding values for the crystalline tiotropium bromide anhydrate which is preferably used within the scope of the present invention may be obtained by multiplying by a conversion factor of 1.2036.
In some cases within the scope of the present invention the term suspension formulation may be used instead of the term suspension. The two terms are to be regarded as interchangeable within the scope of the present invention.
2o The propellant-containing inhalation aerosols or suspension formulations according to the invention may also contain other ingredients such as surface-active agents (surfactants), adjuvants, antioxidants or flavourings.
The surface-active agents (surfactants) which may be contained in the suspensions according to the invention are preferably selected from among Polysorbate 20, Polysorbate 80, Myvacet 9-45, Myvacet 9-08, isopropylmyristate, oleic acid, propyleneglycol, polyethyleneglycol, Brij, ethyloleate, glyceryl trioleate, glyceryl monolaurate, glyceryl monooleate, glyceryl monosterate, glyceryl monoricinoleate, cetylalcohol, sterylalcohol, cetylpyridinium chloride, block polymers, natural oil, 3o ethanol and isopropanol. Of the abovementioned suspension adjuvants Polysorbate 20, Polysorbate 80, Myvacet 9-45, Myvacet 9-08 or isopropylmyristate are preferably used. Myvacet 9-45 or isopropylmyristate are particularly preferred.
Where the suspensions according to the invention contain surfactants, these are preferably present in an amount of 0.0005 - 1 %, more preferably 0.005 - 0.5 %.
The adjuvants optionally contained in the suspensions according to the invention are preferably selected from among alanine, albumin, ascorbic acid, aspartame, betaine, cysteine, phosphoric acid, nitric acid, hydrochloric acid, sulphuric acid and citric acid.
o The percentages specified within the scope of the present invention are always percent by mass. If parts by mass of tiotropium are given in percent by mass, the corresponding values for the crystalline tiotropium bromide anhydrate which is preferably used within the scope of the present invention may be obtained by multiplying by a conversion factor of 1.2036.
In some cases within the scope of the present invention the term suspension formulation may be used instead of the term suspension. The two terms are to be regarded as interchangeable within the scope of the present invention.
2o The propellant-containing inhalation aerosols or suspension formulations according to the invention may also contain other ingredients such as surface-active agents (surfactants), adjuvants, antioxidants or flavourings.
The surface-active agents (surfactants) which may be contained in the suspensions according to the invention are preferably selected from among Polysorbate 20, Polysorbate 80, Myvacet 9-45, Myvacet 9-08, isopropylmyristate, oleic acid, propyleneglycol, polyethyleneglycol, Brij, ethyloleate, glyceryl trioleate, glyceryl monolaurate, glyceryl monooleate, glyceryl monosterate, glyceryl monoricinoleate, cetylalcohol, sterylalcohol, cetylpyridinium chloride, block polymers, natural oil, 3o ethanol and isopropanol. Of the abovementioned suspension adjuvants Polysorbate 20, Polysorbate 80, Myvacet 9-45, Myvacet 9-08 or isopropylmyristate are preferably used. Myvacet 9-45 or isopropylmyristate are particularly preferred.
Where the suspensions according to the invention contain surfactants, these are preferably present in an amount of 0.0005 - 1 %, more preferably 0.005 - 0.5 %.
The adjuvants optionally contained in the suspensions according to the invention are preferably selected from among alanine, albumin, ascorbic acid, aspartame, betaine, cysteine, phosphoric acid, nitric acid, hydrochloric acid, sulphuric acid and citric acid.
Of these, ascorbic acid, phosphoric acid, hydrochloric acid or citric acid are preferred, while hydrochloric acid or citric acid is more preferable.
Where the suspensions according to the invention contain adjuvants, these are s preferably present in an amount of 0.0001-1.0 %, preferably 0.0005-0.1 %, more preferably 0.001-0.01 %, while an amount of from 0.001-0.005 % is particularly preferred according to the invention.
The antioxidants optionally contained in the suspensions according to the invention o are preferably selected from among ascorbic acid, citric acid, sodium edetate, editic acid, tocopherols, butylhydroxytoluene, butylhydroxyanisol and ascorbyl palmitate, of which tocopherols, butylhydroxytoluene, butylhydroxyanisol and ascorbyl palmitate are preferred.
~5 The flavourings which may be contained in the suspensions according to the invention are preferably selected from among peppermint, saccharine, Dentomint~, aspartame and ethereal oils (e.g, cinnamon, aniseed, menthol, camphor), of which peppermint or Dentomint~ is particularly preferred.
2o For administration by inhalation it is necessary to prepare the active substance in finely divided form. The crystalline tiotropium bromide anhydrate which may be obtained as detailed in the experimental section is either ground (micronised or obtained in finely divided form by other technical methods known in principle in the art (such as precipitation and spray drying). Methods of micronising active 25 substances are known in the art. Preferably, after micronisation, the active substance has an average particle size of 0.5 to 10 Nm, preferably 1 to 6 Nm, more preferably 1.5 to 5 Nm. Preferably, at least 50%, more preferably at feast 60%, most preferably at least 70% of the particles of active substance have a particle size which is within the ranges specified above. More preferably, at least 80%, most preferably 3o at least 90% of the particles of active substance have a particle size within the ranges specified above.
Surprisingly, it has been found that it is also possible to prepare suspensions which contain, apart from the abovementioned propellant gases, only the active substance 35 and no other additives. Accordingly, in another aspect, the present invention relates to suspensions which contain only the active substance and no other additives.
The suspensions according to the invention may be prepared by methods known in the art. For this the ingredients of the formulation are mixed with the propellant gas or gases (optionally at low temperatures) and transferred into suitable containers.
Where the suspensions according to the invention contain adjuvants, these are s preferably present in an amount of 0.0001-1.0 %, preferably 0.0005-0.1 %, more preferably 0.001-0.01 %, while an amount of from 0.001-0.005 % is particularly preferred according to the invention.
The antioxidants optionally contained in the suspensions according to the invention o are preferably selected from among ascorbic acid, citric acid, sodium edetate, editic acid, tocopherols, butylhydroxytoluene, butylhydroxyanisol and ascorbyl palmitate, of which tocopherols, butylhydroxytoluene, butylhydroxyanisol and ascorbyl palmitate are preferred.
~5 The flavourings which may be contained in the suspensions according to the invention are preferably selected from among peppermint, saccharine, Dentomint~, aspartame and ethereal oils (e.g, cinnamon, aniseed, menthol, camphor), of which peppermint or Dentomint~ is particularly preferred.
2o For administration by inhalation it is necessary to prepare the active substance in finely divided form. The crystalline tiotropium bromide anhydrate which may be obtained as detailed in the experimental section is either ground (micronised or obtained in finely divided form by other technical methods known in principle in the art (such as precipitation and spray drying). Methods of micronising active 25 substances are known in the art. Preferably, after micronisation, the active substance has an average particle size of 0.5 to 10 Nm, preferably 1 to 6 Nm, more preferably 1.5 to 5 Nm. Preferably, at least 50%, more preferably at feast 60%, most preferably at least 70% of the particles of active substance have a particle size which is within the ranges specified above. More preferably, at least 80%, most preferably 3o at least 90% of the particles of active substance have a particle size within the ranges specified above.
Surprisingly, it has been found that it is also possible to prepare suspensions which contain, apart from the abovementioned propellant gases, only the active substance 35 and no other additives. Accordingly, in another aspect, the present invention relates to suspensions which contain only the active substance and no other additives.
The suspensions according to the invention may be prepared by methods known in the art. For this the ingredients of the formulation are mixed with the propellant gas or gases (optionally at low temperatures) and transferred into suitable containers.
5 The propellant gas-containing suspensions according to the invention mentioned above may be administered using inhalers known in the art (pMDls = pressurised metered dose inhalers). Accordingly, in another aspect, the present invention relates to pharmaceutical compositions in the form of suspensions as hereinbefore described combined with one or more inhalers suitable for administering these ~o suspensions. In addition, the present invention relates to inhalers which are characterised in that they contain the propellant gas-containing suspensions described above according to the invention. The present invention also relates to containers (cartridges) which are fitted with a suitable valve and can be used in a suitable inhaler and which contain one of the above-mentioned propellant gas-~5 containing suspensions according to the invention. Suitable containers (cartridges) and methods of filling these cartridges with the propellant gas-containing suspensions according to the invention are known from the prior art.
In view of the pharmaceutical activity of tiotropium the present invention further relates to the use of the suspensions according to the invention for preparing a drug 2o for administration by inhalation or by nasal route, preferably for preparing a drug for the treatment by inhalation or by nasal route of diseases in which anticholinergics may provide a therapeutic benefit.
Most preferably, the invention further relates to the use of the suspensions according 25 to the invention for preparing a pharmaceutical composition far the treatment by inhalation of respiratory complaints, preferably asthma or COPD.
The Examples that follow serve to illustrate the present invention more fully by way of example, without restricting it to their content.
Starting materials Crystalline tiotro~~ium bromide monohydrate:
The tiotropium obtained according to EP 418 716 A1 may be used to prepare the crystalline tiotropium bromide monohydrate. This is then reacted as described below.
15.0 kg of tiotropium bromide are added to 25.7 kg of water in a suitable reaction vessel. The mixture is heated to 80-90°C and stirred at constant temperature until a clear solution is formed. Activated charcoal (0.8 kg), moistened with water, is suspended in 4.4 kg of water, this mixture is added to the solution containing tiotropium bromide and rinsed with 4.3 kg of water. The mixture thus obtained is stirred for at least 15 min. at 80-90°C and then filtered through a heated filter into an apparatus which has been preheated to an outer temperature of 70°C. The filter is rinsed with 8.6 kg of water. The contents of the apparatus are cooled to a temperature of 20-25°C at a rate of 3-5°C every 20 minutes.
Using cold water the apparatus is cooled further to 10-15°C and crystallisation is completed by stirring for at least another hour. The crystals are isolated using a suction filter drier, the crystal slurry isolated is washed with 9 L of cold water (10-15°C) and cold acetone (10-15°C). The crystals obtained are dried at 25°C for 2 hours in a nitrogen current.
Yield: 13.4 kg of tiotropium bromide mcnohydrate (86 % of theory).
The tiotropium bromide monohydrate obtainable using the method described above was investigated by DSC (Differential Scanning Calorimetry). The DSC diagram ~5 shows two characteristic signals. The first, relatively broad, endothermic signal between 50-120°C can be attributed to the dehydration of the tiotropium bromide rnonohydrate into the anhydrous form. The second, relatively sharp, endothermic peak at 230 ~ 5°C can be put down to the melting of the substance. This data was obtained using a Mettler DSC 821 and evaluated using the Mettler STAR software 2o package. The data was recorded at a heating rate of 10 K/min.
The crystalline tiotropium bromide monohydrate was characterised by IR
spectroscopy. The data was obtained using a Nicolet FTIR spectrometer and evaluated with the Nicolet OMNIC software package, version 3.1. The measurement 25 was carried out with 2.5 Nmol of tiotropium bromide monohydrate in 300 mg of KBr.
The following Table shows some of the essential bands of the IR spectrum.
Wave number (cm-') Attribution Type of oscillation 3570, 3410 O-H elongated oscillation 3105 Aryl C-H elongated oscillation 1730 C=0 elongated oscillation 1260 Epoxide C-O elongated oscillation 1035 Ester C-OC elongated oscillation 720 Thiophene cyclic oscillation The monocrystal X-ray structural analysis carried out showed that the crystalline tiotropium bromide hydrate obtainable by the above process has a simple monoclinic cell with the following dimensions:
a = 18.0774 ~, b = 11.9711 ~, c = 9.9321 ~, ~i = 102.691 °, V = 2096.96 ~3.
These data were obtained using an AFC7R 4-circuit diffractometer (Rigaku) using monochromatic copper KK~, radiation. The structural resolution and refinement of the crystal structure were obtained by direct methods (SHELXS86 Program) and FMLQ-refinement (TeXsan Program).
1o Crystalline tiotropium bromide anhydrite:
The anhydrous form is produced from the crystalline tiotropium bromide monohydrate obtained as described above by careful drying at 80 -100 °C
under reduced pressure, preferably under high vacuum over a period of at least 30 minutes. Alternatively to the drying step at 80 - 100 °C in vacuo the anhydrous form ~5 may also be prepared by storing over dried silica gel at ambient temperature over a period of at least 24 hours.
The crystalline structure of the anhydrous tiotropium bromide was determined from high-resolution X-ray powder data (synchrotron radiation) by a real space mixture 2o using a so-called "simulating annealing" process. A final Rietveld analysis was carried out to refine the structural parameters. These investigations showed that the crystalline tiotropium bromide anhydrite which is used in the suspensions according to the invention is characterised by the elementary cell a = 10.4336(2)A, 25 b = 11.3297(3)A, c = 17.6332(4) ~4 and a = 90°, (i = 105.158(2)° and y = 90° (cell volume = 2011.89(8) A3 ).
To prepare the suspensions according to the invention the crystalline tiotropium bromide anhydrite obtainable by the above process is micronised by methods known in the art, with the exclusion of moisture, to prepare the active substance in the form of the average particle size which corresponds to the specifications according to the invention.
Examples of formulations Suspensions containing other ingredients in addition to active substance and propellant gas:
a) 0.02 % Tiotropium*
0.20 % Polysorbate 20 99.78 HFA 227 %
b) 0.02 % Tiotropium*
1.00 % Isopropylmyristate 98.98 HFA 227 %
c) 0.02 % Tiotropium*
0.3 % Myvacet 9-45 99.68 H FA 227 %
d) 0.04 ! Tiotropium*
1.00 % Myvacet 9-08 98.96 H FA 227 %
e) 0.04 % Tiotropium*
0.04 % Polysorbate 80 99.92 HFA 227 %
f) 0.04 % Tiotropium*
0.005 Oleic acid %
99.955 HFA 227 %
g) 0.02 % Tiotropium*
0.1 % Myvacet 9-45 60.00 HFA 227 %
39.88 HFA 134a %
h) 0.02 % Tiotropium*
0.30 % Isopropylmyristate 20.00 HFA 227 %
79.68 HFA 134a %
i) 0.02 % Tiotropium*
0.01 % Oleic acid 60.00 HFA 227 %
39.97 HFA 134a %
*used in the form he tiotropium bromide of t anhydrate (conversion factor .2036) Suspensions containing only active substance and propellant gas:
0.02 % Tiotropium*
99.98 HFA 227 %
k) 0.02 Tiotropium*
%
99.98 HFA 134a %
I) 0.04 Tiotropium*
%
99.96 HFA 227 %
m) 0.04 Tiotropium*
%
99.96 HFA 134a %
n) 0.02 Tiotropium*
%
20.00 HFA 227 %
79.98 HFA 134a %
o) 0.02 Tiotropium*
%
60. 00 H FA 227 %
39.98 HFA 134a %
p) 0.04 Tiotropium*
%
40.00 H FA 227 %
59.96 HFA 134a %
q) 0.04 Tiotropium*
%
80.00 HFA 227 %
19.96 HFA 134a %
* used in the form of the tiotropium bromide anhydrite (conversion factor 1.2036)
In view of the pharmaceutical activity of tiotropium the present invention further relates to the use of the suspensions according to the invention for preparing a drug 2o for administration by inhalation or by nasal route, preferably for preparing a drug for the treatment by inhalation or by nasal route of diseases in which anticholinergics may provide a therapeutic benefit.
Most preferably, the invention further relates to the use of the suspensions according 25 to the invention for preparing a pharmaceutical composition far the treatment by inhalation of respiratory complaints, preferably asthma or COPD.
The Examples that follow serve to illustrate the present invention more fully by way of example, without restricting it to their content.
Starting materials Crystalline tiotro~~ium bromide monohydrate:
The tiotropium obtained according to EP 418 716 A1 may be used to prepare the crystalline tiotropium bromide monohydrate. This is then reacted as described below.
15.0 kg of tiotropium bromide are added to 25.7 kg of water in a suitable reaction vessel. The mixture is heated to 80-90°C and stirred at constant temperature until a clear solution is formed. Activated charcoal (0.8 kg), moistened with water, is suspended in 4.4 kg of water, this mixture is added to the solution containing tiotropium bromide and rinsed with 4.3 kg of water. The mixture thus obtained is stirred for at least 15 min. at 80-90°C and then filtered through a heated filter into an apparatus which has been preheated to an outer temperature of 70°C. The filter is rinsed with 8.6 kg of water. The contents of the apparatus are cooled to a temperature of 20-25°C at a rate of 3-5°C every 20 minutes.
Using cold water the apparatus is cooled further to 10-15°C and crystallisation is completed by stirring for at least another hour. The crystals are isolated using a suction filter drier, the crystal slurry isolated is washed with 9 L of cold water (10-15°C) and cold acetone (10-15°C). The crystals obtained are dried at 25°C for 2 hours in a nitrogen current.
Yield: 13.4 kg of tiotropium bromide mcnohydrate (86 % of theory).
The tiotropium bromide monohydrate obtainable using the method described above was investigated by DSC (Differential Scanning Calorimetry). The DSC diagram ~5 shows two characteristic signals. The first, relatively broad, endothermic signal between 50-120°C can be attributed to the dehydration of the tiotropium bromide rnonohydrate into the anhydrous form. The second, relatively sharp, endothermic peak at 230 ~ 5°C can be put down to the melting of the substance. This data was obtained using a Mettler DSC 821 and evaluated using the Mettler STAR software 2o package. The data was recorded at a heating rate of 10 K/min.
The crystalline tiotropium bromide monohydrate was characterised by IR
spectroscopy. The data was obtained using a Nicolet FTIR spectrometer and evaluated with the Nicolet OMNIC software package, version 3.1. The measurement 25 was carried out with 2.5 Nmol of tiotropium bromide monohydrate in 300 mg of KBr.
The following Table shows some of the essential bands of the IR spectrum.
Wave number (cm-') Attribution Type of oscillation 3570, 3410 O-H elongated oscillation 3105 Aryl C-H elongated oscillation 1730 C=0 elongated oscillation 1260 Epoxide C-O elongated oscillation 1035 Ester C-OC elongated oscillation 720 Thiophene cyclic oscillation The monocrystal X-ray structural analysis carried out showed that the crystalline tiotropium bromide hydrate obtainable by the above process has a simple monoclinic cell with the following dimensions:
a = 18.0774 ~, b = 11.9711 ~, c = 9.9321 ~, ~i = 102.691 °, V = 2096.96 ~3.
These data were obtained using an AFC7R 4-circuit diffractometer (Rigaku) using monochromatic copper KK~, radiation. The structural resolution and refinement of the crystal structure were obtained by direct methods (SHELXS86 Program) and FMLQ-refinement (TeXsan Program).
1o Crystalline tiotropium bromide anhydrite:
The anhydrous form is produced from the crystalline tiotropium bromide monohydrate obtained as described above by careful drying at 80 -100 °C
under reduced pressure, preferably under high vacuum over a period of at least 30 minutes. Alternatively to the drying step at 80 - 100 °C in vacuo the anhydrous form ~5 may also be prepared by storing over dried silica gel at ambient temperature over a period of at least 24 hours.
The crystalline structure of the anhydrous tiotropium bromide was determined from high-resolution X-ray powder data (synchrotron radiation) by a real space mixture 2o using a so-called "simulating annealing" process. A final Rietveld analysis was carried out to refine the structural parameters. These investigations showed that the crystalline tiotropium bromide anhydrite which is used in the suspensions according to the invention is characterised by the elementary cell a = 10.4336(2)A, 25 b = 11.3297(3)A, c = 17.6332(4) ~4 and a = 90°, (i = 105.158(2)° and y = 90° (cell volume = 2011.89(8) A3 ).
To prepare the suspensions according to the invention the crystalline tiotropium bromide anhydrite obtainable by the above process is micronised by methods known in the art, with the exclusion of moisture, to prepare the active substance in the form of the average particle size which corresponds to the specifications according to the invention.
Examples of formulations Suspensions containing other ingredients in addition to active substance and propellant gas:
a) 0.02 % Tiotropium*
0.20 % Polysorbate 20 99.78 HFA 227 %
b) 0.02 % Tiotropium*
1.00 % Isopropylmyristate 98.98 HFA 227 %
c) 0.02 % Tiotropium*
0.3 % Myvacet 9-45 99.68 H FA 227 %
d) 0.04 ! Tiotropium*
1.00 % Myvacet 9-08 98.96 H FA 227 %
e) 0.04 % Tiotropium*
0.04 % Polysorbate 80 99.92 HFA 227 %
f) 0.04 % Tiotropium*
0.005 Oleic acid %
99.955 HFA 227 %
g) 0.02 % Tiotropium*
0.1 % Myvacet 9-45 60.00 HFA 227 %
39.88 HFA 134a %
h) 0.02 % Tiotropium*
0.30 % Isopropylmyristate 20.00 HFA 227 %
79.68 HFA 134a %
i) 0.02 % Tiotropium*
0.01 % Oleic acid 60.00 HFA 227 %
39.97 HFA 134a %
*used in the form he tiotropium bromide of t anhydrate (conversion factor .2036) Suspensions containing only active substance and propellant gas:
0.02 % Tiotropium*
99.98 HFA 227 %
k) 0.02 Tiotropium*
%
99.98 HFA 134a %
I) 0.04 Tiotropium*
%
99.96 HFA 227 %
m) 0.04 Tiotropium*
%
99.96 HFA 134a %
n) 0.02 Tiotropium*
%
20.00 HFA 227 %
79.98 HFA 134a %
o) 0.02 Tiotropium*
%
60. 00 H FA 227 %
39.98 HFA 134a %
p) 0.04 Tiotropium*
%
40.00 H FA 227 %
59.96 HFA 134a %
q) 0.04 Tiotropium*
%
80.00 HFA 227 %
19.96 HFA 134a %
* used in the form of the tiotropium bromide anhydrite (conversion factor 1.2036)
Claims (9)
1) Suspensions of crystalline tiotropium bromide anhydrate in the propellant gases HFA 227 and/or HFA 134a, optionally in admixture with one or more other propellant gases selected from the group consisting of propane, butane, pentane, dimethylether, CHClF2, CH2F2, CF3CH3, isobutane, isopentane and neopentane.
2) Suspensions according to claim 1, characterised in that they contain between 0.001 and 0.8% tiotropium.
3) Suspensions according to claim 1 or 2, characterised in that they contain as other ingredients surface-active agents (surfactants), adjuvants, antioxidants and/or flavourings.
4) Suspensions according to claim 3, characterised in that they contain as surface-active agents (surfactants) one or more compounds selected from the group consisting of Polysorbate 20, Polysorbate 80, Myvacet 9-45, Myvacet 9-08, isopropylmyristate, oleic acid, propyleneglycol, polyethyleneglycol, Brij, ethyl oleate, glyceryl trioleate, glyceryl monolaurate, glyceryl monooleate, glyceryl monosterate, glyceryl monoricinoleate, cetylalcohol, sterylalcohol, cetylpyridinium chloride, block polymers, natural oil, ethanol and isopropanol .
5) Suspensions according to claim 3, characterised in that they contain as adjuvants one or more compounds selected from the group consisting of alanine, albumin, ascorbic acid, aspartame, betaine, cysteine, phosphoric acid, nitric acid, hydrochloric acid, sulphuric acid and citric acid.
6) Suspensions according to claim 3, characterised in that they contain as antioxidants one or more compounds selected from the group consisting of ascorbic acid, citric acid, sodium edetate, editic acid, tocopherols, butylhydroxytoluene, butylhydroxyanisol and ascorbyl palmitate.
7) Suspensions according to claim 1 or 2, characterised in that they contain no other ingredients apart from the active substance and the propellant gas or gases.
8) Use of a suspension according to one of claims 1 to 7 for preparing a pharmaceutical composition, preferably for preparing a pharmaceutical composition for the treatment by inhalation or nasal route of diseases in which anticholinergics may confer a therapeutic benefit.
9) Use according to claim 8, characterised in that the diseases are respiratory complaints, preferably asthma or COPD.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10214264A DE10214264A1 (en) | 2002-03-28 | 2002-03-28 | HFA suspension formulations of an anhydrate |
| DE10214264.5 | 2002-03-28 | ||
| PCT/EP2003/002899 WO2003082244A2 (en) | 2002-03-28 | 2003-03-20 | Hfa-suspension formulation of an anhydrate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2479638A1 CA2479638A1 (en) | 2003-10-09 |
| CA2479638C true CA2479638C (en) | 2011-01-04 |
Family
ID=28050990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2479638A Expired - Fee Related CA2479638C (en) | 2002-03-28 | 2003-03-20 | Hfa-suspension formulations of crystalline tiotropium bromide anhydrate |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1492498A2 (en) |
| JP (1) | JP5147158B2 (en) |
| KR (1) | KR101005717B1 (en) |
| CN (1) | CN1642525A (en) |
| AU (1) | AU2003221509B2 (en) |
| BR (1) | BR0308709A (en) |
| CA (1) | CA2479638C (en) |
| DE (1) | DE10214264A1 (en) |
| EA (1) | EA008610B1 (en) |
| EC (1) | ECSP045322A (en) |
| HR (1) | HRP20040890A2 (en) |
| IL (1) | IL163696A0 (en) |
| ME (1) | ME00246B (en) |
| MX (1) | MXPA04009338A (en) |
| NO (1) | NO20044004L (en) |
| NZ (1) | NZ536030A (en) |
| PL (1) | PL371295A1 (en) |
| RS (1) | RS52481B (en) |
| UA (1) | UA79776C2 (en) |
| WO (1) | WO2003082244A2 (en) |
| ZA (1) | ZA200405637B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8324266B2 (en) | 2009-05-29 | 2012-12-04 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| US8808713B2 (en) | 2009-05-29 | 2014-08-19 | Pearl Thereapeutics, Inc. | Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1881980T1 (en) * | 2005-05-02 | 2012-12-31 | Boehringer Ingelheim International Gmbh | Novel crystalline forms of tiotropium bromide |
| AU2006243239A1 (en) * | 2005-05-02 | 2006-11-09 | Boehringer Ingelheim International Gmbh | Crystalline forms of tiotropium bromide |
| AU2015201037C1 (en) * | 2009-05-29 | 2017-07-27 | Pearl Therapeutics, Inc. | Respiratory delivery of active agents |
| RU2696582C2 (en) | 2013-03-15 | 2019-08-05 | Перл Терапьютикс, Инк. | Methods and systems for conditioning disperse crystalline materials |
| WO2018051132A1 (en) * | 2016-09-19 | 2018-03-22 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3931041C2 (en) * | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Esters of thienyl carboxylic acids with amino alcohols, their quaternization products, processes for their preparation and medicaments containing them |
| ES2193726T3 (en) * | 1998-08-04 | 2003-11-01 | Jago Res Ag | MEDICINAL AEROSOL FORMULATIONS. |
| GB0009592D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory combinations |
| GB0009605D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Medicaments |
| GB0009583D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory formulations |
| GB0009606D0 (en) * | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Therapeutic combinations |
| DE10113366A1 (en) * | 2001-03-20 | 2002-09-26 | Boehringer Ingelheim Pharma | Medicament for treating inflammatory or obstructive respiratory diseases, e.g. asthma or chronic obstructive pulmonary disease, containing synergistic combination of anticholinergic agent and endothelin antagonist |
| DE10111058A1 (en) * | 2001-03-08 | 2002-09-12 | Boehringer Ingelheim Pharma | New drug compositions based on anticholinergics and NK¶1¶ receptor antagonists |
| MXPA03003752A (en) * | 2000-10-31 | 2003-09-30 | Boehringer Ingelheim Pharma | Novel medicament compositions. |
-
2002
- 2002-03-28 DE DE10214264A patent/DE10214264A1/en not_active Withdrawn
-
2003
- 2003-03-20 BR BR0308709-3A patent/BR0308709A/en active Pending
- 2003-03-20 CN CNA038072475A patent/CN1642525A/en active Pending
- 2003-03-20 CA CA2479638A patent/CA2479638C/en not_active Expired - Fee Related
- 2003-03-20 EA EA200401159A patent/EA008610B1/en unknown
- 2003-03-20 UA UA20041008758A patent/UA79776C2/en unknown
- 2003-03-20 EP EP03717219A patent/EP1492498A2/en not_active Withdrawn
- 2003-03-20 ME MEP-2008-473A patent/ME00246B/en unknown
- 2003-03-20 PL PL03371295A patent/PL371295A1/en not_active Application Discontinuation
- 2003-03-20 AU AU2003221509A patent/AU2003221509B2/en not_active Expired
- 2003-03-20 NZ NZ536030A patent/NZ536030A/en not_active IP Right Cessation
- 2003-03-20 KR KR1020047015174A patent/KR101005717B1/en active IP Right Grant
- 2003-03-20 RS YU86004A patent/RS52481B/en unknown
- 2003-03-20 IL IL16369603A patent/IL163696A0/en unknown
- 2003-03-20 WO PCT/EP2003/002899 patent/WO2003082244A2/en active Application Filing
- 2003-03-20 MX MXPA04009338A patent/MXPA04009338A/en active IP Right Grant
- 2003-03-20 JP JP2003579782A patent/JP5147158B2/en not_active Expired - Lifetime
-
2004
- 2004-07-15 ZA ZA2004/05637A patent/ZA200405637B/en unknown
- 2004-09-23 NO NO20044004A patent/NO20044004L/en not_active Application Discontinuation
- 2004-09-27 HR HR20040890A patent/HRP20040890A2/en not_active Application Discontinuation
- 2004-09-28 EC EC2004005322A patent/ECSP045322A/en unknown
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8324266B2 (en) | 2009-05-29 | 2012-12-04 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| US8703806B2 (en) | 2009-05-29 | 2014-04-22 | Pearl Therapeutics, Inc. | Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents |
| US8808713B2 (en) | 2009-05-29 | 2014-08-19 | Pearl Thereapeutics, Inc. | Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| US9463161B2 (en) | 2009-05-29 | 2016-10-11 | Pearl Therapeutics, Inc. | Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003082244A2 (en) | 2003-10-09 |
| RS52481B (en) | 2013-02-28 |
| NO20044004L (en) | 2004-10-05 |
| ECSP045322A (en) | 2005-01-28 |
| YU86004A (en) | 2006-08-17 |
| ME00246B (en) | 2011-05-10 |
| HRP20040890A2 (en) | 2005-06-30 |
| BR0308709A (en) | 2005-01-04 |
| EA200401159A1 (en) | 2005-04-28 |
| ZA200405637B (en) | 2005-07-27 |
| WO2003082244A3 (en) | 2004-02-05 |
| PL371295A1 (en) | 2005-06-13 |
| AU2003221509B2 (en) | 2008-01-24 |
| JP5147158B2 (en) | 2013-02-20 |
| DE10214264A1 (en) | 2003-10-16 |
| KR101005717B1 (en) | 2011-01-05 |
| JP2005527550A (en) | 2005-09-15 |
| EP1492498A2 (en) | 2005-01-05 |
| CN1642525A (en) | 2005-07-20 |
| KR20040098022A (en) | 2004-11-18 |
| NZ536030A (en) | 2006-07-28 |
| IL163696A0 (en) | 2005-12-18 |
| EA008610B1 (en) | 2007-06-29 |
| MEP47308A (en) | 2011-02-10 |
| AU2003221509A1 (en) | 2003-10-13 |
| MXPA04009338A (en) | 2005-01-25 |
| UA79776C2 (en) | 2007-07-25 |
| CA2479638A1 (en) | 2003-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7736627B2 (en) | HFA suspension formulations containing an anticholinergic | |
| CA2450961C (en) | Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition | |
| MXPA03003221A (en) | Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament. | |
| CA2544352C (en) | Crystalline anhydrate with anticholinergic effect | |
| ZA200602343B (en) | Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same | |
| ZA200602342B (en) | Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same | |
| CA2479638C (en) | Hfa-suspension formulations of crystalline tiotropium bromide anhydrate | |
| CA2479640C (en) | Hfa suspension formulations containing an anticholinergic | |
| US7244415B2 (en) | HFA suspension formulations of an anhydrate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20220301 |
|
| MKLA | Lapsed |
Effective date: 20200831 |